Are we closer to finding biomarkers for identifying acute drug-induced liver injury?

Abstract

Biomarkers in MedicineVol. 7, No. 3 General content - EditorialFree AccessAre we closer to finding biomarkers for identifying acute drug-induced liver injury?Daniel J Antoine, Philip Starkey Lewis, Christopher E Goldring & B Kevin ParkDaniel J Antoine* Author for correspondenceMRC Centre for Drug Safety Science, Department of Molecular & Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Sherrington Buildings, Ashton Street, Liverpool, L69 3GE, UK. Search for more papers by this authorEmail the corresponding author at d.antoine@liv.ac.uk, Philip Starkey LewisMRC Centre for Drug Safety Science, Department of Molecular & Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Sherrington Buildings, Ashton Street, Liverpool, L69 3GE, UKSearch for more papers by this author, Christopher E GoldringMRC Centre for Drug Safety Science, Department of Molecular & Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Sherrington Buildings, Ashton Street, Liverpool, L69 3GE, UKSearch for more papers by this author & B Kevin ParkMRC Centre for Drug Safety Science, Department of Molecular & Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Sherrington Buildings, Ashton Street, Liverpool, L69 3GE, UKSearch for more papers by this authorPublished Online:4 Jun 2013https://doi.org/10.2217/bmm.13.42AboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit Keywords: acetaminophenHMGB1miR-122qualificationOver recent years, there has been a considerable effort to identify and develop new biomarkers of acute drug-induced liver injury (DILI). It is clear that the development and qualification of sensitive and specific hepatic biomarkers that permit quantitative assessment of the translation between preclinical and clinical studies is urgently required. The potential for novel biomarkers to provide enhanced understanding of the fundamental mechanisms that result in clinical DILI is becoming increasingly recognized. Furthermore, there is a great need for mechanistic biomarkers that can bridge between preclinical models and the clinical situation of DILI. These will therefore enable us to understand the human relevance of predictive models of acute DILI and the interpretation of data generated from such models. Such biomarkers would not only accelerate the pace of drug development but also provide a point-of-care test to enable patient and/or DILI-specific treatment stratification once a new drug is licensed. Currently, the number of putative biomarkers that hold some clinical utility is low, mainly because less attention has been placed on the science of drug safety compared with drug efficacy [1].The current assessment of acute DILI & a critical evaluationPresently, only a small number of blood-based tests are used to assess liver injury or dysfunction in humans, and assessment within drug development is heavily dependent upon hepatic histological interpretation. The ‘classical’ blood-based tests include the serum concentration of total bilirubin (TBL) and the activity assessment of the enzymes ALP, AST and ALT. Elevations in the activity of these enzymes may indicate injury to biliary cells or hepatocytes, while changes in TBL represent changes in hepatic function [2]. Although the assay of ALT has become the primary screening tool to detect acute DILI, it is not without its problems. Changes in enzyme activities are not specific for DILI and can occur in a number of disease processes, including viral hepatitis, fatty liver disease and liver cancer [3]. In addition, elevations in ALP may also be attributed to hyperthyroidism or bone disease and increases in ALT and AST can also be the result of myocardial damage or muscle damage from extreme exercise. In addition, the methods used to quantify ALT activity have not been standardized and a robust definition of normal reference ranges has not been agreed upon; these inevitably depend upon the population group defined as normal. Assay measurements also vary between laboratories. Furthermore, although ALT activity is regarded as sensitive for detecting liver injury when it occurs, it is not sensitive with respect to time/kinetics. ALT activity alone therefore offers little predictive value given the rarity of idiosyncratic DILI and that an ALT elevation represents probable injury to the liver after injury has occurred. Therefore, ALT activity is often combined with the liver-specific assessment of TBL as part of Hy’s law. This is currently the only accepted regulatory model to assess significant acute DILI. However, there are several reported examples of when a subject qualifies as a Hy’s law case and this has been previously reviewed [1,4]. This diagnosis of a Hy’s law case is often delayed and often occurs when treatment is discontinued. This highlights the space for improvement and modification to Hy’s law criteria that novel biomarkers can fill. Therefore, taking these deficiencies into account, there has been a considerable effort to identify and develop new biomarkers that can inform the mechanistic basis of DILI and provide potential measures for patient management and treatment stratification.Which biomarkers have been identified & developed & what is their clinical utility?Considering the need to develop and qualify new biomarkers for acute DILI (and injury to other organs), a significant level of resources have recently been directed towards this and a number of public–private consortia have been developed; namely the Predictive Safety Testing Consortium and Safer And Faster Evidence-based Translation consortium [5]. Important and noteworthy progresses have been made in the development of biomarkers for renal drug safety evaluation, which have been qualified for use by various regulatory authorities. The lessons learnt from these can be applied to the liver [6,7]. In particular, the concept that new biomarkers should be used to complement existing ones and not to replace them has arisen. With respect to DILI, a number of targeted biomarkers have been identified as having preclinical sensitivity and specificity for their utility to assess acute liver injury, such as α-glutathione S-transferase, arginase 1 and 4-hydroxyphenylpyruvate dioxygenase [8]. In addition, sensitive mechanistic biomarkers have also been reported. These range from highly liver-specific miRNAs such as miR-122 [9], to markers of epithelial cell apoptosis and necrosis such as KRT18 [10], and to markers of mitochondrial dysfunction such as GLDH [11] and markers of immune modulation and hepatic necrosis such as HMGB1 [10]. Clinical utility of miR-122, HMGB1, KRT18 and GLDH has been recognized and they have recently been demonstrated to report on liver injury associated with acetaminophen overdose in a more sensitive manner than currently used indicators of liver injury [11,12]. Moreover, clinical findings also reveal that a number of these markers hold enhanced prognostic capability over current methods following acetaminophen overdose [13,14]. However, while these markers offer a sensitive indication of liver injury, information about the mechanism of toxicity, enhanced prognostic utility and a clear route for patient stratification, a major limitation is that these conclusions are mainly drawn on clinical evidence following relatively common acetaminophen overdose and have not been assessed in rare cases of idiosyncratic DILI. A better understanding of the kinetics of these current biomarkers in human or animal biofluids is required so that we can have a stronger basis on how to interpret the data. Furthermore, the majority of biomarkers under evaluation reflect hepatic injury when it occurs and their assessment of hepatic regeneration/drug adaptation has not been evaluated. For example, considering ALT activity from a regulatory point of view, elevations in ALT activity are worrisome with respect to liver safety. Frequent and relatively large elevations in ALT activity are associated with treatments that do not pose a clinical liver-safety issue, such as heparins [15] and tacrine [16]. Indeed, the mechanism by which ALT is released from the hepatocyte has never been studied in detail and the quantitative relationship between cell injury per se and the number of hepatocytes damaged has not been established. The challenge now is to identify or assess currently proposed biomarkers (on their own or in combination) that can distinguish between benign elevations in ALT activity and those that represent serious DILI outcome. The refinement of a recently described clinically relevant porcine model of predictable acute liver failure following acetaminophen overdose may be appropriate to discover mechanisms and biomarkers of sublethal injury, recovery or adaptation [17].Are we too quick to write off currently used markers of acute DILI?The assay of serum ALT activity has become the primary method to assess acute liver injury. Although not formally qualified against human histology for DILI, ALT is widely ‘validated’ and ‘qualified’ through its widespread use and ease of assay. Although ALT activity has substantial limitations, it can be a very useful biomarker if understood and used properly. Often, elevations in serum ALT activity are understood and interpreted wrongly. The origins and reasons for why the misinterpretation of elevations in ALT activity have come into wide acceptance have been recently and elegantly reviewed [4].Within this review, Senior proposes new interpretations relating to ALT activity and suggests how they might lend themselves to better general use, and that suitable revisions in guidance, teaching approaches and clinical practice will need to reflect this. We now build upon this to initiate discussion and debate as to the best course of action to develop new biomarkers of DILI: ▪ Serum ALT activity is not a test of liver function but of liver cell injury, and the quantitative relationship between ALT activity and the actual number of dying hepatocytes requires further characterization;▪ Whole-liver dysfunction determines severity of injury and serum TBL is one measure of liver function;▪ The combined biomarker of ALT and TBL has high sensitivity for when liver injury occurs and has great hepatic specificity that represents the current standard to refine, build on or surpass any putative acute liver injury biomarker;▪ ALT has been shown to have different functional isoforms. Therefore, refinement of the current assay should reflect this and may improve data quality;▪ There is a need for defined and standardized assays for ALT activity (or another chosen novel biomarker) and what should be adapted as a true normal reference value;▪ If elevations in ALT activity (or the chosen novel biomarker) over the normal range are seen during assessment, the test should be repeated as a matter of urgency, so that evidence-based decisions can be made as to the direction of injury (progression or resolution);▪ New mechanism-based biomarkers, which reflect particular cellular processes involved in DILI and can be used alongside current methods, should offer a clear rationale for patient stratification and novel pathways for therapeutic intervention.ConclusionIt is clear that there is a need for novel biomarkers to assess liver injury associated with drug use and clear progress has been made and clinical utility shown regarding ‘mechanism-based’ biomarkers. It is also clear that no single biomarker will be the answer and that a panel approach of novel biomarkers alongside a more intelligent use of currently used biomarkers represents the way forward. Studies should therefore be designed to understand what purpose the biomarker is fit for and to define its context of use in a prospective manner. With this guidance in mind, a note of caution should also be adopted as to the interpretation of data from the assessment of novel markers that are qualified or evaluated based on data in high-incidence populations (such as acetaminophen overdose) and applying them to rare idiosyncratic acute DILI when high negative predictive values can confound judgement of sensitivity and specificity. In summary, there are now clearly a number of DILI biomarkers that hold great potential. When using these markers, lessons from the qualification of recent renal safety biomarkers can be applied to the liver. DILI is a complex multicellular and multimechanism disease; therefore, it is logical that a battery of complimentary biomarkers that reflect specific cellular processes is required in the first instance rather than simply displacing current markers.Financial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.References1 Watkins PB. Drug safety sciences and the bottleneck in drug development. Clin. Pharmacol. Ther.89(6),788–790 (2011).Crossref, Medline, CAS, Google Scholar2 Antoine DJ, Mercer AE, Williams DP, Park BK. Mechanism-based bioanalysis and biomarkers for hepatic chemical stress. Xenobiotica39(8),565–577 (2009).Crossref, Medline, CAS, Google Scholar3 Ozer J, Ratner M, Shaw M, Bailey W, Schomaker S. The current state of serum biomarkers of hepatotoxicity. Toxicology245(3),194–205 (2008).Crossref, Medline, CAS, Google Scholar4 Senior JR. Alanine aminotransferase: a clinical and regulatory tool for detecting liver injury – past, present, and future. Clin. Pharmacol. Ther.92(3),332–339 (2012).Crossref, Medline, CAS, Google Scholar5 Matheis K, Laurie D, Andriamandroso C et al. A generic operational strategy to qualify translational safety biomarkers. Drug Discov. Today16(13–14),600–608 (2011).Crossref, Medline, Google Scholar6 Vaidya VS, Ozer JS, Dieterle F et al. Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. Nat. Biotechnol.28(5),478–485 (2010).Crossref, Medline, CAS, Google Scholar7 Bonventre JV, Vaidya VS, Schmouder R, Feig P, Dieterle F. Next-generation biomarkers for detecting kidney toxicity. Nat. Biotechnol.28(5),436–440 (2010).Crossref, Medline, CAS, Google Scholar8 Bailey WJ, Holder D, Patel H et al. A performance evaluation of three drug-induced liver injury biomarkers in the rat: alpha-glutathione S-transferase, arginase 1, and 4-hydroxyphenyl-pyruvate dioxygenase. Toxicol. Sci.130(2),229–244 (2012).Crossref, Medline, CAS, Google Scholar9 Wang K, Zhang S, Marzolf B et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc. Natl Acad. Sci. USA106(11),4402–4407 (2009).Crossref, Medline, CAS, Google Scholar10 Antoine DJ, Williams DP, Kipar A et al. High-mobility group box-1 protein and keratin-18, circulating serum proteins informative of acetaminophen-induced necrosis and apoptosis in vivo. Toxicol. Sci.112(2),521–531 (2009).Crossref, Medline, CAS, Google Scholar11 McGill MR, Sharpe MR, Williams CD, Taha M, Curry SC, Jaeschke H. The mechanism underlying acetaminophen-induced hepatotoxicity in humans and mice involves mitochondrial damage and nuclear DNA fragmentation. J. Clin. Invest.122(4),1574–1583 (2012).Crossref, Medline, CAS, Google Scholar12 Antoine DJ, Dear JW, Starkey-Lewis P et al. Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital. Hepatology doi:10.1002/hep.26294 (2013) (Epub ahead of print).Medline, Google Scholar13 Antoine DJ, Jenkins RE, Dear JW et al. Molecular forms of HMGB1 and keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity. J. Hepatol.56(5),1070–1079 (2012).Crossref, Medline, CAS, Google Scholar14 Starkey Lewis PJ, Dear J et al. Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology54(5),1767–1776 (2011).Crossref, Medline, CAS, Google Scholar15 Harrill AH, Roach J, Fier I et al. The effects of heparins on the liver: application of mechanistic serum biomarkers in a randomized study in healthy volunteers. Clin. Pharmacol. Ther.92(2),214–220 (2012).Crossref, Medline, CAS, Google Scholar16 Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with Alzheimer’s disease. JAMA271(13),992–998 (1994).Crossref, Medline, CAS, Google Scholar17 Lee KC, Palacios Jimenez C, Alibhai H et al. A reproducible, clinically relevant, intensively managed, pig model of acute liver failure for testing of therapies aimed to prolong survival. Liver Int.33(4),544–551 (2013).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByPotential deleterious effects of paracetamol dose regime used in Nigeria versus that of the United States of AmericaToxicology Reports, Vol. 9Novel biomarkers for potential risk stratification of drug induced liver injury (DILI)1 December 2019 | Medicine, Vol. 98, No. 50Biomarkers of translational medicine27 November 2018 | Russian Journal of Biotherapy, Vol. 17, No. 1WITHDRAWN: Reference intervals for putative biomarkers of drug-induced liver injury and liver regeneration in healthy human volunteersJournal of Hepatology, Vol. 15Translational and Mechanistic Biomarkers of Drug-Induced Liver Injury – Candidates and Qualification Strategies21 March 2018Predictive Strategies for ADRs – Biomarkers and In Vitro ModelsProfiles of mi RNA s in serum in severe acute drug induced liver injury and their prognostic significance29 November 2016 | Liver International, Vol. 37, No. 5Transformative biomarkers for drug-induced liver injury: are we there yet?Daniel J Antoine & James W Dear18 January 2017 | Biomarkers in Medicine, Vol. 11, No. 2Laboratory‐based biomarkers to improve causality assessment in drug‐induced liver injury1 March 2017 | Clinical Liver Disease, Vol. 9, No. 2Recent advances in biomarkers and therapeutic interventions for hepatic drug safety – false dawn or new horizon?17 March 2016 | Expert Opinion on Drug Safety, Vol. 15, No. 5Translational Mechanistic Biomarkers and Models for Predicting Drug-Induced Liver Injury24 March 2016Mechanism-Based Markers of Drug-Induced Liver Injury to Improve the Physiological Relevance and Predictivity of In Vitro ModelsApplied In Vitro Toxicology, Vol. 1, No. 3Mechanistic Safety Biomarkers for Drug-Induced Liver Injury19 June 2015Enzyme-Specific Sensors via Aggregation of Charged p- Phenylene Ethynylenes2 March 2015 | ACS Applied Materials & Interfaces, Vol. 7, No. 9Drug-induced liver injury: what was new in 2013?19 April 2014 | Expert Opinion on Drug Metabolism & Toxicology, Vol. 10, No. 7Stratification of paracetamol overdose patients using new toxicity biomarkers: current candidates and future challenges22 January 2014 | Expert Review of Clinical Pharmacology, Vol. 7, No. 2Safety biomarkers for drug-induced liver injury – current status and future perspectives1 January 2014 | Toxicol. Res., Vol. 3, No. 2 Vol. 7, No. 3 Follow us on social media for the latest updates Metrics History Published online 4 June 2013 Published in print June 2013 Information© Future Medicine LtdKeywordsacetaminophenHMGB1miR-122qualificationFinancial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download